[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,890,478
  • Shares Outstanding, K 195,806
  • Annual Sales, $ 502,080 K
  • Annual Income, $ -724,930 K
  • EBIT $ -523 M
  • EBITDA $ -512 M
  • 60-Month Beta 1.09
  • Price/Sales 27.19
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 55.89% (-4.76%)
  • Historical Volatility 41.94%
  • IV Percentile 49%
  • IV Rank 41.96%
  • IV High 80.30% on 02/05/26
  • IV Low 38.24% on 06/12/25
  • Expected Move (DTE 15) 6.08 (8.57%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 1,927
  • Volume Avg (30-Day) 1,908
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 50,479
  • Open Int (30-Day) 46,341
  • Expected Range 64.86 to 77.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 10
  • High Estimate $-0.50
  • Low Estimate $-0.91
  • Prior Year $-0.88
  • Growth Rate Est. (year over year) +20.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.35 +3.79%
on 04/29/26
84.75 -16.29%
on 04/28/26
+1.24 (+1.78%)
since 03/27/26
3-Month
62.77 +13.02%
on 03/03/26
84.94 -16.48%
on 02/12/26
-8.16 (-10.32%)
since 01/29/26
52-Week
31.77 +123.29%
on 05/29/25
84.94 -16.48%
on 02/12/26
+34.52 (+94.78%)
since 04/29/25

Most Recent Stories

More News
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.94 (+1.76%)
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April...

BBIO : 70.94 (+1.76%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.94 (+1.76%)
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p

BBIO : 70.94 (+1.76%)
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically...

BBIO : 70.94 (+1.76%)
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.94 (+1.76%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.94 (+1.76%)
How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks

Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock’s growth potential.

TECH : 51.95 (-2.92%)
BBIO : 70.94 (+1.76%)
XBI : 128.90 (-1.72%)
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified...

BBIO : 70.94 (+1.76%)
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 70.94 (+1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 75.04
2nd Resistance Point 73.19
1st Resistance Point 72.06
Last Price 70.94
1st Support Level 69.08
2nd Support Level 67.23
3rd Support Level 66.11

See More

52-Week High 84.94
Last Price 70.94
Fibonacci 61.8% 64.63
Fibonacci 50% 58.36
Fibonacci 38.2% 52.08
52-Week Low 31.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.